Repositive Release: New Research Shows How Repositive Platform Can Be Used To Leverage Direct To Consumer Genomic Data For Research
Cambridge, 24 July 2017 ... New research promoted at the European Conference for Computational Biology (ECCB) in Prague shows how the Repositive platform can be used to find and create an open access human genotype data collection, based on online available 23andMe data contributed to the public domain.
Manuel Corpas and Richard Shaw, from Repositive, the company that created the world’s largest portal for accessing human genomic research data, used publicly available data from 23andMe to create an Open Access dataset of genotype information for more than 2400 individuals.
The preprint was published in bioRxiv, a public archive specialising in providing preprints for biology.
Manuel Corpas, Scientific Lead at Repositive, said: “Currently, aggregated genome datasets with unrestricted public use are unusually rare, but this approach shows how through using the Repositive platform, it is possible to create an Open Access reference dataset for human genotypes which can be used for research, and most importantly, complies with all data consent.”
Fiona Nielsen, CEO of Repositive added: “This research shows the potential of using the Repositive platform to make the available data sources from around the world easily findable and accessible. With this new reference data set based on publicly available 23andme data we have shown how data from direct-to-consumer genetic testing can be leveraged to create resources for further research.”
Manuel Corpas and Richard Shaw, from Repositive, the company that created the world’s largest portal for accessing human genomic research data, used publicly available data from 23andMe to create an Open Access dataset of genotype information for more than 2400 individuals.
The preprint was published in bioRxiv, a public archive specialising in providing preprints for biology.
Manuel Corpas, Scientific Lead at Repositive, said: “Currently, aggregated genome datasets with unrestricted public use are unusually rare, but this approach shows how through using the Repositive platform, it is possible to create an Open Access reference dataset for human genotypes which can be used for research, and most importantly, complies with all data consent.”
Fiona Nielsen, CEO of Repositive added: “This research shows the potential of using the Repositive platform to make the available data sources from around the world easily findable and accessible. With this new reference data set based on publicly available 23andme data we have shown how data from direct-to-consumer genetic testing can be leveraged to create resources for further research.”